Patrick Amstutz - Molecular Partners CEO, CoFounder
| MOLN Stock | CHF 5.10 0.25 5.15% |
Insider
Patrick Amstutz is CEO, CoFounder of Molecular Partners AG
| Age | 48 |
| Phone | (41) 44 755 77 07 |
| Web | www.molecularpartners.com |
Molecular Partners Management Efficiency
The company has return on total asset (ROA) of 0.3163 % which means that it generated a profit of $0.3163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6246 %, meaning that it generated $0.6246 on every $100 dollars invested by stockholders. Molecular Partners' management efficiency ratios could be used to measure how well Molecular Partners manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Marco Marotta | Relief Therapeutics Holding | 37 | |
| FCMA CGMA | Santhera Pharmaceuticals Holdin | 60 | |
| Fabienne Gschwind | Evolva Holding SA | 50 | |
| Neville MD | Santhera Pharmaceuticals Holdin | N/A | |
| Oliver Strub | Santhera Pharmaceuticals Holdin | 60 | |
| Jeremy CPA | Relief Therapeutics Holding | 33 | |
| Oliver MBA | Evolva Holding SA | 54 | |
| Jack Weinstein | Relief Therapeutics Holding | 66 | |
| Damian Heller | Basilea Pharmaceutica AG | 57 | |
| Guy MD | Idorsia | 67 | |
| Lutz Wevelsiep | Basilea Pharmaceutica AG | N/A | |
| Kaspar Mueller | Evolva Holding SA | 60 | |
| Marc MD | Basilea Pharmaceutica AG | 59 | |
| Jeremy Meinen | Relief Therapeutics Holding | 32 | |
| David Veitch | Basilea Pharmaceutica AG | 58 | |
| Christopher Wick | Relief Therapeutics Holding | N/A | |
| Eva Kalias | Santhera Pharmaceuticals Holdin | N/A | |
| Dario Eklund | Santhera Pharmaceuticals Holdin | 55 | |
| Drew CroninFine | Relief Therapeutics Holding | N/A | |
| Martine Clozel | Idorsia | 68 | |
| Thomas Meier | Santhera Pharmaceuticals Holdin | 61 | |
Management Performance
| Return On Equity | 0.62 | |||
| Return On Asset | 0.32 |
Molecular Partners Leadership Team
Elected by the shareholders, the Molecular Partners' board of directors comprises two types of representatives: Molecular Partners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Molecular. The board's role is to monitor Molecular Partners' management team and ensure that shareholders' interests are well served. Molecular Partners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Molecular Partners' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Steiner, VP Research | ||
| Thomas Schwerzmann, VP HR | ||
| Michael Stumpp, Ex CoFounder | ||
| Andreas EMBA, Advisor | ||
| Alexander Zurcher, COO Board | ||
| Seth Lewis, Communications Relations | ||
| Patrick Amstutz, CEO, CoFounder | ||
| Renate Gloggner, Ex Board | ||
| Michael Pitzner, Compliance Counsel |
Molecular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Molecular Partners a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.62 | |||
| Return On Asset | 0.32 | |||
| Profit Margin | 0.62 % | |||
| Operating Margin | 0.61 % | |||
| Current Valuation | (39.23 M) | |||
| Shares Outstanding | 36.04 M | |||
| Shares Owned By Insiders | 14.13 % | |||
| Shares Owned By Institutions | 45.01 % | |||
| Price To Earning | 2.02 X | |||
| Price To Book | 0.89 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.